GlassScriptPhysician profile
Kelley Winfrey
NPI 1386076321
$1,732.93
in general payments reported to CMS, 2019-2025
24 companies · $621 in 2025
The $621 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $173 · 2023: $421 · 2024: $518 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,559.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $214.95 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $191.46 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $189.86 | 2023-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $144.20 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $137.29 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $137.17 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $93.94 | 2022-2025 | Capvaxive, Gardasil 9, Gardasil |
| Abbott Laboratories | $90.64 | 2023-2025 | Freestyle Libre 3 |
| Pfizer INC. | $55.63 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.02 | 2024 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $49.37 | 2024-2025 | |
| Antares Pharma, INC. | $42.15 | 2022 | |
| Abbvie INC. | $40.89 | 2023-2024 | Vraylar |
| Astellas Pharma US INC | $38.55 | 2024 | Veozah |
| Esperion Therapeutics, INC. | $33.33 | 2023-2025 | Nexletol |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $30.66 | 2022-2023 | Quviviq |
| Tolmar, INC. | $30.21 | 2025 | Jatenzo |
| Sanofi Pasteur INC. | $30.04 | 2023-2025 | |
| Shield Therapeutics INC | $26.37 | 2022-2025 | |
| Eisai INC. | $25.91 | 2025 | |
| Hologic Sales and Service, LLC | $22.66 | 2023 | Aptima, Thinprep 2000 Processor |
| Axsome Therapeutics, INC. | $21.81 | 2022 | |
| Indivior INC. | $20.06 | 2023 | Sublocade |
| Inspire Medical Systems, INC. | $13.76 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelley Winfrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.